Navigation Links
Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents
Date:4/22/2008

DUBLIN, Calif., April 22 /PRNewswire/ -- Microchip Biotechnologies, Inc. (MBI) announces that it has entered into a multi-patent license agreement with GE Healthcare that significantly enhances MBI's intellectual property portfolio supporting the development of lab-on-a-chip devices. The patents cover design and methods for creating integrated fluidic microchip devices.

"Licensing these fundamental patents continues to build our strong intellectual property position in microfluidic devices," said Dr. Stevan Jovanovich, President and CEO of MBI. "Microfluidic devices will play a critical role in next-generation instrumentation that delivers fully-automated, cost-effective bioassay solutions in the life sciences, applied sciences, and molecular diagnostics."

California-based MBI will use the technology licensed from GE Healthcare to develop and commercialize easy to use Sample-To-Answer systems using advanced microfluidic technologies. Microfluidics deals with the behavior, precise control, and manipulation of microliter and nanoliter volumes of fluids to perform life science assays. Microfluidics technologies are essential for development of lab-on-a-chip devices for DNA analysis and molecular diagnostics. Microfluidic devices are smaller, faster and cheaper than the laboratory benchtop instruments that they are designed to replace, and are exquisitely suited for clinical and forensic systems used at the bedside or in the field.

About Microchip Biotechnologies

Microchip Biotechnologies, Inc. is an early-stage privately-held company located in Dublin, California that is developing advanced nanofluidic sample preparation and analytical instrumentation for Life Sciences, Applied Sciences, and Diagnostics markets. These solutions are based on MBI's proprietary "NanoBioProcessor(TM) platform and associated "Microscale-on-Chip-Valves" (MOV(TM)). More details can be found on the Company's website: http://www.microchipbiotech.com.


'/>"/>
SOURCE Microchip Biotechnologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian Centre for DNA Barcoding to Participate in Microchip Biotechnologies Early Access Program for Microchip-Based DNA Sample Preparation and Cycle Sequencing
2. Microchip Biotechnologies, Inc. Collaborating With Stanford University on Developing a Front End Microfluidic-Based Sample Preparation System for Pyrosequencing Platforms
3. Team develops energy-efficient microchip
4. Quick microchip test for dangerous antibiotic resistant bacteria
5. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
6. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
7. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
8. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
9. Maven Biotechnologies, LLC to Present at BIOCOM Investor Conference
10. Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center
11. CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... VA (PRWEB) , ... December 07, 2016 , ... ... medical journal has concluded that “in the setting of previously treated, advanced pancreatic ... refinement in defining the optimal patient population and timing of blood sampling may ...
(Date:12/7/2016)... - OncoQuest Inc. ("OncoQuest"), a biopharmaceutical company focused ... for the treatment of cancer, today announced that ... Program with Cytovance Biologics ( Oklahoma City, ... product. Supported by recent positive interim clinical results ... cancer patients, OncoQuest has engaged Cytovance to establish ...
(Date:12/7/2016)...  Biocom, the association for the California ... of 21 st Century Cures legislation in Congress. The ... 392-26 vote and in the Senate on December 7 by ... Joe Panetta , president & CEO of Biocom: ... millions of patients around the world. The measure culminates three ...
(Date:12/7/2016)... , Dec. 7, 2016  Genprex, Inc. a ... immunogene therapy treatments, today announced that it has ... a leading strategic communications and advisory firm, to ... The program will combine investor relations, public relations ... raising the profile of Genprex and its lead ...
Breaking Biology Technology:
(Date:11/16/2016)... CLARA, Calif. , Nov. 16, 2016 ... enhancing user experience and security for consumer electronics, ... for the financial and retail industry, today announced ... secure and convenient way to authenticate users of ... uses Sensory,s TrulySecure™ software which requires ...
(Date:11/15/2016)... , Nov 15, 2016 Research and ... Global Forecast to 2021" report to their offering. ... ... USD 16.18 Billion by 2021 from USD 6.21 Billion in 2016, ... Growth of the bioinformatics market is driven by the ...
(Date:11/14/2016)... SANTA CLARA, Calif. , Nov. 14, ... of the biometric identification market, Frost & ... Global Frost & Sullivan Award for Visionary ... leading player in the biometric identification market ... a multi-modal verification solution for instant, seamless, ...
Breaking Biology News(10 mins):